What is Erste Group Bank’s Estimate for BMY FY2027 Earnings?

Posted by Brenda Bartman on Oct 23rd, 2026

Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Equities research analysts at Erste Group Bank increased their FY2027 earnings per share (EPS) estimates for Bristol Myers Squibb in a research report issued to clients and investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will earn $6.56 per share for the year, up from their prior forecast of $6.53. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.56 per share.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Several other research firms have also commented on BMY. Morgan Stanley reiterated an “underweight” rating and set a $41.00 price target (up from $40.00) on shares of Bristol Myers Squibb in a report on Wednesday, October 7th. Citigroup restated a “neutral” rating and set a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Bank of America reduced their target price on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research note on Friday, October 9th. Wells Fargo & Company dropped their price target on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 13th. Finally, Zacks Research raised shares of Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 23rd. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $64.88.

Check Out Our Latest Stock Analysis on BMY

Bristol Myers Squibb Stock Up 3.2%

Shares of NYSE:BMY opened at $63.10 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The business has a fifty day moving average of $63.31 and a two-hundred day moving average of $60.32. The stock has a market cap of $128.89 billion, a P/E ratio of 13.90, a PEG ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.64.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date is Friday, October 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.05% of the company’s stock.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Primecap Management Co. CA acquired a new stake in Bristol Myers Squibb in the 2nd quarter valued at approximately $1,436,115,000. Legal & General Group Plc acquired a new position in Bristol Myers Squibb during the second quarter worth $980,862,000. BlackRock Inc. lifted its stake in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. State Street Corp boosted its position in shares of Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares during the period. Finally, Caisse de depot et placement du Quebec purchased a new position in shares of Bristol Myers Squibb during the second quarter worth $243,646,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Fresh oncology and pulmonary-fibrosis updates, including data headed to the ESMO 2026 Congress and positive Phase 3 results, are reinforcing confidence in BMY’s pipeline and helping support recent share momentum. Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight
Positive Sentiment: Bristol Myers Squibb is launching a national collaboration with IHI to expand access to cancer clinical trials, potentially improving research reach and supporting the company’s long-term oncology strategy. IHI and Bristol Myers Squibb Launch National Collaborative
Positive Sentiment: Compared with Pfizer, BMY has posted a steadier revenue trajectory, with continuous year-over-year growth across recent quarters. Its dividend also has a more comfortable payout ratio, strengthening the stock’s appeal to income-oriented investors. Bristol Myers Squibb vs. Pfizer: Consistency vs. Scale in Revenue
Neutral Sentiment: BMY’s upcoming quarterly report is drawing attention. Earlier results benefited from Camzyos and oncology products, while the company’s FY 2026 EPS guidance remains a valuation support; nevertheless, analysts expect year-over-year earnings pressure in the upcoming quarter. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline
Negative Sentiment: Generic competition across BMY’s older portfolio, particularly as legacy drugs face pricing and market pressures, could weigh on growth. Eliquis remains a key strength, but investors are monitoring concentration and replacement-product risks. Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.